Form 4: ImmunityBio Director Acquires Stock Options

John Owen Brennan, a director of ImmunityBio, Inc., acquired stock options for 77,633 shares on June 11, 2024.

Summary

• On June 11, 2024, John Owen Brennan, a director of ImmunityBio, Inc. (IBRX), acquired stock options for 77,633 shares.
• The exercise price of these options is $5.96.
• The options vest on the earlier of June 11, 2025, or the day before the next annual meeting of stockholders, contingent upon Brennan's continued service as a Service Provider.
• The options expire on June 11, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock option grants, which is a common practice. The director's acquisition of options could be interpreted as a positive sign, but it's not a major event.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon the director's continued service, suggesting an incentive for long-term commitment.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors and executives in biotech companies, similar to companies like Amgen (AMGN) and Gilead Sciences (GILD).
• The vesting schedule, contingent on continued service, is also standard practice to incentivize long-term commitment, aligning with industry norms observed at companies like Regeneron (REGN) and Vertex Pharmaceuticals (VRTX).

Stakeholder Impact

• The stock option grant could potentially align the director's interests with those of shareholders, as the value of the options is tied to the company's stock performance.

Key Dates